Tower Research Capital LLC (Trc) Fate Therapeutics Inc Transaction History

Tower Research Capital LLC (Trc)

  • $3.39 Billion
  • Q3 2025

A detailed history of Tower Research Capital LLC (Trc) transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 11,937 shares of FATE stock, worth $11,459. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,937
Previous 23,758 49.76%
Holding current value
$11,459
Previous $26,000 42.31%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
SELL
$0.92 - $1.3 $10,875 - $15,367
-11,821 Reduced 49.76%
11,937 $15,000
Q2 2025

Aug 14, 2025
BUY
$0.68 - $1.67 $4,672 - $11,476
6,872 Added 40.7%
23,758 $26,000
Q1 2025

May 15, 2025
BUY
$0.79 - $1.87 $1,704 - $4,035
2,158 Added 14.65%
16,886 $13,000
Q4 2024

Feb 13, 2025
BUY
$1.61 - $3.35 $12,627 - $26,274
7,843 Added 113.91%
14,728 $24,000
Q3 2024

Nov 14, 2024
SELL
$3.12 - $5.57 $47,523 - $84,842
-15,232 Reduced 68.87%
6,885 $24,000
Q2 2024

Aug 13, 2024
BUY
$3.26 - $7.08 $45,366 - $98,525
13,916 Added 169.69%
22,117 $72,000
Q1 2024

May 15, 2024
SELL
$3.54 - $8.35 $24,893 - $58,717
-7,032 Reduced 46.16%
8,201 $60,000
Q4 2023

Feb 13, 2024
SELL
$1.65 - $3.94 $42,228 - $100,836
-25,593 Reduced 62.69%
15,233 $56,000
Q3 2023

Nov 14, 2023
BUY
$2.02 - $5.04 $32,356 - $80,730
16,018 Added 64.57%
40,826 $86,000
Q2 2023

Aug 14, 2023
BUY
$4.76 - $6.59 $71,304 - $98,718
14,980 Added 152.42%
24,808 $118,000
Q1 2023

May 09, 2023
BUY
$4.24 - $11.12 $6,648 - $17,436
1,568 Added 18.98%
9,828 $56,000
Q4 2022

Feb 10, 2023
SELL
$9.86 - $23.83 $451,380 - $1.09 Million
-45,779 Reduced 84.71%
8,260 $83,000
Q3 2022

Nov 10, 2022
BUY
$21.04 - $36.06 $981,579 - $1.68 Million
46,653 Added 631.64%
54,039 $1.21 Million
Q2 2022

Aug 15, 2022
SELL
$17.78 - $42.39 $89,824 - $214,154
-5,052 Reduced 40.62%
7,386 $183,000
Q1 2022

May 12, 2022
BUY
$29.67 - $60.28 $251,957 - $511,897
8,492 Added 215.21%
12,438 $482,000
Q4 2021

Feb 14, 2022
BUY
$47.84 - $64.34 $13,921 - $18,722
291 Added 7.96%
3,946 $231,000
Q3 2021

Nov 15, 2021
BUY
$59.27 - $95.73 $24,478 - $39,536
413 Added 12.74%
3,655 $217,000
Q2 2021

Aug 16, 2021
SELL
$67.25 - $92.52 $1.33 Million - $1.83 Million
-19,746 Reduced 85.9%
3,242 $281,000
Q1 2021

May 17, 2021
BUY
$72.16 - $117.4 $1.14 Million - $1.85 Million
15,777 Added 218.79%
22,988 $1.9 Million
Q4 2020

Feb 16, 2021
BUY
$38.09 - $100.95 $167,100 - $442,867
4,387 Added 155.35%
7,211 $656,000
Q3 2020

Nov 16, 2020
SELL
$30.41 - $40.5 $282,660 - $376,447
-9,295 Reduced 76.7%
2,824 $113,000
Q2 2020

Aug 13, 2020
BUY
$20.21 - $35.23 $244,924 - $426,952
12,119 New
12,119 $416,000
Q4 2019

Feb 07, 2020
SELL
$13.39 - $20.73 $103,986 - $160,989
-7,766 Closed
0 $0
Q3 2019

Nov 05, 2019
BUY
$15.47 - $22.5 $120,140 - $174,735
7,766 New
7,766 $121,000
Q1 2019

May 14, 2019
SELL
$13.15 - $18.71 $420 - $598
-32 Closed
0 $0
Q4 2018

Feb 14, 2019
SELL
$11.48 - $16.98 $67,536 - $99,893
-5,883 Reduced 99.46%
32 $0
Q3 2018

Nov 13, 2018
BUY
$8.75 - $16.29 $51,756 - $96,355
5,915 New
5,915 $96,000
Q2 2018

Aug 15, 2018
SELL
$9.16 - $13.48 $650 - $957
-71 Closed
0 $0
Q1 2018

May 15, 2018
BUY
$6.3 - $13.77 $447 - $977
71 New
71 $1,000
Q4 2017

Feb 09, 2018
SELL
$3.94 - $6.64 $38,154 - $64,301
-9,684 Closed
0 $0
Q3 2017

Nov 14, 2017
BUY
$2.6 - $4.31 $25,178 - $41,738
9,684
9,684 $39,000

Others Institutions Holding FATE

# of Institutions
156
Shares Held
81.5M
Call Options Held
46.4K
Put Options Held
17.5K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $93.1M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email